Cytochrome P450 3A4 and P-glycoprotein (ABCB1) pathway (CYP3A4/P-gp)

Colchicine pharmacokinetics are primarily governed by the Cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein (P-gp) efflux transporter (StatPearls, 2023). CYP3A4 is responsible for the oxidative metabolism of colchicine in the liver, while P-gp, encoded by the ABCB1 gene, facilitates the biliary and renal excretion of the drug and limits its absorption in the gastrointestinal tract (FDA, 2012). Because colchicine has a narrow therapeutic index, the functional integrity of these two pathways is critical for preventing systemic toxicity (PubMed, PMID: 20653354). Inhibition of either CYP3A4 or P-gp by concomitant medications, such as clarithromycin or ketoconazole, can lead to a significant increase in colchicine plasma concentrations, potentially resulting in fatal multi-organ failure (NIH, 2021). Conversely, induction of these pathways by drugs like rifampin can reduce colchicine efficacy in treating conditions like gout or familial Mediterranean fever (Journal of Clinical Pharmacology, 2010).

Other names

Colchicine metabolic pathwayCYP3A4-mediated metabolism and P-gp-mediated transportABCB1 and CYP3A4 mediated clearanceColchicine pharmacokinetic pathway

Colchicine acts as a substrate for both the CYP3A4 enzyme and the P-glycoprotein efflux pump; drugs targeting this pathway typically inhibit or induce these proteins to alter colchicine's systemic exposure.